参考文献/References:
[1]Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.[2]Byrne CD,Targher G.NAFLD:a multisystem disease[J].Hepatol,2015,62 (1 Suppl):S47-S64.[3]Shakir AK,Suneja U,Kevin R,et al.Overview of Pediatric Nonalcoholic Fatty Liver Disease:A Guide for General Practitioners Okla State Med Assoc[J].J Okla State Med Assoc,2018,111(8):806-811.[4]Doycheva I,Issa D,Watt KD,et al.Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States[J].Clin Gastroenterol,2008(52):339-346.[5]European Association for the Study of the Liver (EASL);European Association for the Study of Diabetes (EASD);European Association for the Study of Obesity (EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].Diabetologia,2016,59(6):1121-1140. [6]Koopman N,Molinaro A,Nieuwdorp M,et al.Review article:can bugs be drugs?The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2019,50(6):628-639. [7]Gaggini M,Morelli M,Buzzigoli E,et al.Non-Alcoholic Fatty Liver Disease(NAFLD)and Its Connection with Insulin Resistance,Dyslipidemia,Atherosclerosis and Coronary Heart Disease[J].Nutrients,2013,5(5):1544-1560.[8]Higgins J.Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1.The Cochrane Collaboration[J].Naunyn Schmiedebergs Archiv Für Experimentelle Pathologie Und Pharmakologie,2008,5(2):S38.[9]Belfort R,Harrison SA,Brown K,et al.A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis[J].N Engl J Med,2006,355(22):2297-2307.[10]Balas B,Belfort R,Harrison SA,et al.Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis [J].Hepatol,2007,47(4):565-570.[11]Aithal GP,Thomas JA,Kaye PV,et al.Randomized,Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis[J].Gastroenterology,2008,135(4):1176-1184.[12]项岫秀,张慧芹,刘秀玲,等.吡格列酮对2型糖尿病合并非酒精性脂肪肝病患者血浆同型半胱氨酸水平的影响[J].临床荟萃,2009,24(15):1349-1350.[13]Sanyal AJ,Chalasani N,Kowdley KV,et al.Pioglitazone,Vit.Amin E,or Placebo for Nonalcoholic Steatohepatitis[J].N Engl J Med,2010,362(18):1675-1685.[14]徐园园,纪易斐.吡格列酮对糖尿病合并非酒精性脂肪肝炎的疗效观察[J].中华全科医学,2011,9(6):895,916.[15]呙劲松,陈艳.吡格列酮对糖耐量异常合并非酒精性脂肪肝患者血浆瘦素水平及胰岛素抵抗的影响[J].中南医学科学杂志,2014(4):379-381.[16]Cusi K,Orsak B,Bril F,et al.Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:A Randomized Trial[J].Ann Intern Med,2016,165(5):305-315.[17]熊玮,唐淑亚,唐顺利.吡格列酮治疗非酒精性脂肪肝的疗效分析[J].中国社区医师,2018,34(22):65,67.[18]Anushiravani A,Haddadi N,Pourfarmanbar M,et al.Treatment options for nonalcoholic fatty liver disease:a double-blinded randomized placebo-controlled trial[J].Eur J Gastroenterol Hepatol,2019,31(5):613-617.[19]Younossi ZM.Non-alcoholic fatty liver disease--a global public health perspective[J].Hepatol,2019,70(3):531-544.[20]Hardy T,Oakley F,Anstee QM,et al.Nonalcoholic fatty liver disease:pathogenesis and disease spectrum[J].Annu Rev Pathol Mech Dis,2016(11):451-496.[21]Ekstedt M,Nasr P,Kechagias S.Natural History of NAFLD[J].Curr Hepatol Rep,2017,16(4):391-397.[22]Marchesini G,Brizi M,Bianchi G,et al.Nonalcoholic fatty liver disease:a feature of the metabolic syndrome[J].Diabetes,2001,50(8):1844-1850.[23]Saadati S,Sadeghi A,Mansour A,et al.Curcumin and inflammation in non-alcoholic fatty liver disease:a randomized,placebo controlled clinical trial[J].BMC Gastroenterol,2019,19(1):133.[24]Takao T,Kumagai C,Hisakawa N,et al.Effect of 17beta-estradiol on tumor necrosis factor-alpha-induced cytotoxicity in the human peripheral T lymphocytes[J].J Endocfinol,2005,184(1):191-197.[25]Miyazaki Y,Mahankali A,Matsuda M,et al.Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic Patines[J].Clin Endocrinol Metab,200,87(6):2784-2791.
相似文献/References:
[1]谢雨萌,毛乾国.非酒精性脂肪肝患者中医体质及相关证型研究[J].医学信息,2018,31(07):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
XIE Yu-meng,MAO Qian-guo.Study on TCM Constitution and Correlative Syndromes of Nonalcoholic Fatty Liver Patients[J].Medical Information,2018,31(13):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
[2]刘 瑜,王 星,代 萌,等.2型糖尿病合并非酒精性脂肪肝的危险因素研究[J].医学信息,2018,31(23):108.[doi:10.3969/j.issn.1006-1959.2018.23.029]
LIU Yu,WANG Xing,DAI Meng,et al.Study on Risk Factors of Type 2 Diabetes Mellitus with Non-alcoholic Fatty liver Disease[J].Medical Information,2018,31(13):108.[doi:10.3969/j.issn.1006-1959.2018.23.029]
[3]蒙春越.格列美脲联合吡格列酮治疗老年2型糖尿病合并
高血压患者的疗效分析[J].医学信息,2019,32(13):84.[doi:10.3969/j.issn.1006-1959.2019.13.023]
MENG Chun-yue.Efficacy Analysis of Glimepiride Combined with Pioglitazone in the Treatment of Elderly Patients with Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2019,32(13):84.[doi:10.3969/j.issn.1006-1959.2019.13.023]
[4]黄丽玲,吴春城,梁惠卿,等.血清标志物壳多糖酶3样蛋白1评价肝纤维化的研究[J].医学信息,2021,34(10):32.[doi:10.3969/j.issn.1006-1959.2021.10.009]
HUANG Li-ling,WU Chun-cheng,LIANG Hui-qing,et al.Serum Marker Chitinase 3-like Protein 1 in the Evaluation of Liver Fibrosis[J].Medical Information,2021,34(13):32.[doi:10.3969/j.issn.1006-1959.2021.10.009]
[5]郭月欢,甘惠中.幽门螺旋杆菌感染与非酒精性脂肪肝的相关性研究[J].医学信息,2022,35(08):89.[doi:10.3969/j.issn.1006-1959.2022.08.021]
GUO Yue-huan,GAN Hui-zhong.Correlation Between Helicobacter Pylori Infection and Nonalcoholic Fatty Liver Disease[J].Medical Information,2022,35(13):89.[doi:10.3969/j.issn.1006-1959.2022.08.021]
[6]秦 莉,邱秀霞.肝病降脂颗粒对非酒精性脂肪肝患者肝脏生化及血脂水平的影响[J].医学信息,2022,35(21):65.[doi:10.3969/j.issn.1006-1959.2022.21.014]
QIN Li,QIU Xiu-xia.Effect of Ganbing Jiangzhi Granules on Liver Biochemistry and Blood Lipid Levels in Patients with Nonalcoholic Fatty Liver Disease[J].Medical Information,2022,35(13):65.[doi:10.3969/j.issn.1006-1959.2022.21.014]
[7]陈 超,陈冯梅.血清尿酸/肌酐比值与老年人非酒精性脂肪肝的相关性研究[J].医学信息,2023,36(19):71.[doi:10.3969/j.issn.1006-1959.2023.19.014]
CHEN Chao,CHEN Feng-mei.Correlation Between Serum Uric Acid/Creatinine Ratio and Nonalcoholic Fatty Liver Disease in the Elderly[J].Medical Information,2023,36(13):71.[doi:10.3969/j.issn.1006-1959.2023.19.014]
[8]王 晶,曹名波.非酒精性脂肪肝相关基因多态性的研究进展[J].医学信息,2023,36(24):183.[doi:10.3969/j.issn.1006-1959.2023.24.043]
WANG Jing,CAO Ming-bo.Research Progress on Gene Polymorphisms Related to Non-alcoholic Fatty Liver Disease[J].Medical Information,2023,36(13):183.[doi:10.3969/j.issn.1006-1959.2023.24.043]